ZFIN Image: Bezerra et al., 2024, Figure 3

Image

Figure Caption

Figure 3

Activity of 3-NAntC (peptide 3) in breast cancer cell lines compared to benign cells. Tumor (MDA-MB-231 and MCF-7) and benign (HDFa, HMEC, and MCF10A) cell lines were treated with 3-NAntC for 24, 48, and 72 h at the concentration range of 0.2–1.0 µg/mL. Cellular viability assay was conducted using the MTT method. Data are shown as mean ± SEM of at least three independent assays in triplicate. (a–c) Benign cell lines treated with the same concentrations of 3-NAntC were compared to the control (0 µg/mL) using two-way ANOVA and a Bonferroni post hoc test. (d–f) MDA-MB-231 and MCF-7 tumor cell lines were treated with various concentrations of 3-NAntC and compared to the HMEC benign cell line using two-way ANOVA and a Bonferroni post hoc test, # p < 0.05, and #### p < 0.0001.

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Molecules